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Abstract 
Background: B-type natriuretic peptide (BNP) is well known to increase as a result of 
left ventricular systolic dysfunction and is a useful diagnostic marker for heart failure. 
The purpose of this study was to assess the incremental value of BNP for predicting 
obstructive coronary artery disease (CAD) on computed tomography angiography 
(CTA) in patients with suspected CAD. 
Methods: This was an observational analysis of patients with stable CAD undergoing 
CTA in our institution between 2008 April and 2014 June. A consecutive 947 patients 
with suspected CAD underwent 64-slice CTA were enrolled. Obstructive CAD was 
defined as more than 50% luminal narrowing. We divided the patients into 2 groups 
according to median BNP value (20.3 pg/ml). Duke clinical score for obstructive CAD 
was calculated for each patient. 
Results: Obstructive CAD was found in 273 (28.0%) patients. Median follow-up 
periods was 37 months (interquartile range 21 to 55 months). Kaplan-Meier curves 
showed BNP above median was significantly associated with major adverse cardiac 
events (P=0.001). In multivariable logistic analysis, patients with BNP above median 
were associated with the presence of obstructive CAD, as compared with BNP below 
median (Odds ratio, 2.55; 95% confidence interval [CI], 1.79–3.63; P<0.001). 
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Analyzing the incremental value of the Duke clinical score and BNP, the predictive 
value of the Duke clinical score (area under the curve [AUC], 0.714) could be increased 
by BNP (AUC 0.745 for the combined model; P<0.001). Addition of BNP to a model 
containing the Duke clinical score resulted in continuous net reclassification 
improvement of 0.39 (95% CI, 0.26–0.53; P<0.001).  
Conclusions: BNP might provide an incremental improvement in the detection of 
obstructive CAD on CTA when combined with a conventional cardiovascular risk score. 
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Introduction 
   The early detection of coronary artery disease (CAD) is one of the most important 
tasks in medical practice. Contrast-enhanced computed tomography angiography (CTA) 
has been proposed as an emerging tool for stenosis detection and characterization and 
quantification of coronary atherosclerotic plaques [1–3]. Previous studies have 
demonstrated high diagnostic accuracy of CTA for the detection and assessment of the 
severity of CAD when compared with invasive coronary angiography [4,5] and the 
incremental prognostic value of CAD detected by CTA in patients with suspected CAD 
[6]. The presence of obstructive CAD on CTA is significantly associated with an 
increased risk of major cardiac events [6,7]. Conversely, patients with no CAD on CTA 
have a better prognosis [8,9]. 
B-type natriuretic peptide (BNP) is well known to increase as a result of left 
ventricular (LV) systolic dysfunction and is recommended by the European Society of 
Cardiology guidelines as a test to rule out heart failure [10]. However, some previous 
studies have shown that an increased BNP can identify inducible ischemia by standard 
noninvasive stress test independent of LV ejection fraction (LVEF) [11]. Recently, some 
studies have suggested an association between BNP levels and the extent of coronary 
atherosclerosis [11, 12]. N-terminal pro-BNP (NT pro-BNP) is also associated with 
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calcium score independent of conventional cardiovascular risk factors [12]. Although an 
increased BNP is associated with worse prognosis in patients with stable CAD, it is not 
clear whether BNP is a useful tool for the detection of CAD. The purpose of this study 
was to evaluate the association between plasma BNP level and the presence of 
obstructive CAD as assessed by CTA. 
 
Materials and Methods 
Study Population 
   The present study was a retrospective cohort study based on a consecutive 1269 
patients with suspected CAD not previously treated with percutaneous coronary 
intervention or coronary artery bypass grafting and prior myocardial infarction who 
underwent CTA in our institution between April 2008 and June 2014. We excluded 
patients with poor CTA imaging due to motion artifact (n=39), atrial fibrillation (n=78), 
previous heart failure (n=26), acute myocardial infarction (n=13), lower LVEF (less 
than 50%) (n=77), hypertrophic cardiomyopathy or left ventricular hypertrophy (n=29), 
and missing BNP value (n=60). This study thus comprised 947 patients (Figure 1). The 
study was approved by an institutional review committee and the subjects gave 
informed consent. Patient demographic information, cardiovascular risk factors, 
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laboratory findings, and symptoms were recorded. The following cardiac risk factors 
were considered. Hypertension was defined as the presence of current treatment with 
antihypertensive drugs or otherwise as a systolic blood pressure of ≥140 mmHg and/or 
diastolic blood pressure of ≥90 mmHg. We defined dyslipidemia if a patient met one or 
more of the following criteria: serum low density lipoprotein (LDL) cholesterol level 
≥140 mg/dL, high density lipoprotein (HDL) cholesterol level 40 mg/dL, serum fasting 
triglyceride level ≥150 mg/dL, or taking medications to treat dyslipidemia [13]. 
Diabetes mellitus was defined as a fasting glucose level of ≥126 mg/dl or treatment with 
oral hypoglycemic agents or insulin. The estimated glomerular filtration rate (eGFR) 
was calculated with the following equation: eGFR = 194 × (serum creatinine)(-1.094) × 
(age)(-0.287) (× 0.739 if female) [14]. 
From these data, the Duke clinical score for obstructive CAD was calculated for 
each patient [15,16]. Duke clinical score model was shown in appendix. A blood sample 
was withdrawn prior to CTA. BNP was measured using the ARCHITECT BNP assay 
(ABBOTT JAPAN Diagnostics, Tokyo, Japan). Measurement of BNP was routinely 
performed in all patients undergoing CTA at the examination. The detection limit was 
5.8 pg/ml, and the upper measurement limit was 14510 pg/ml. However, BNP values 
were missing for 60 patients, who were censored from further statistical analysis (Figure 
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1). We divided the patients into two groups according to median BNP value. BNP below 
median was <20.3 pg/ml (n = 476); BNP above median was ≥20.3 pg/ml (n = 469). 
LVEF was measured by echocardiography. 
 
CTA Protocol 
   Scanning was performed with a Philips Brilliance-64 scanner (Philips Medical 
Systems, Cleveland, Ohio) with 64×0.625-mm detector configuration. Scanning was 
performed in retrospective gating at 120 to 140 kV and 600 to 1050 mA, 0.2 pitch, and 
with ECG-based tube current modulation. The cardiac phase best demonstrating each 
artery (usually 75% of the RR interval) was analyzed using a dedicated computed 
tomography workstation (Philips CT Brilliance Workspace, Philips Medical Systems). 
In some cases, additional reconstructions were made at different time points of the RR 
interval. Nonionic contrast (iopamidol 370 mg/ml; Schering AG, Berlin, Germany) was 
injected intravenously at a rate of 4 to 5 m/l. Automated peak enhancement detection in 
the ascending aorta was used for timing of the bolus using a threshold of +100 
Hounsfield units (HU). The data acquisition was performed during an inspiratory breath 
hold of approximately 10 s. Atenolol (25 mg) orally was administered 12 hour before 
the examination to decrease heart rate to less than 60 beats/min. When heart rate below 
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60 bpm could not be achieved using atenolol 25mg, heart rate control with a target of 60 
bpm was achieved using 12.5–25mg landiolol, an ultra-short-acting beta-adrenergic 
blocking agent, injected before data acquisition [17]. All patients received sublingual 
nitroglycerin (0.3 mg) 5 min before the scan. 
 
CTA Analysis 
   All CTA scans were analyzed by two experienced readers who were unaware of 
clinical presentation, patient characteristics, and biomarker analysis. Image display 
settings for lumen and plaque quantification were determined according to previously 
published data [18]. The coronary artery tree was segmented according to a American 
Heart Association classification [19]. The degree of lesion severity was graded into 3 
groups: normal was defined as no coronary artery plaques and no obstruction of the 
coronary lumen, nonobstructive was defined as an estimated obstruction of coronary 
luminal diameter of ≤50%, and obstructive was defined as an estimated obstruction of 
coronary luminal diameter of >50%. The total coronary artery calcium burden was 
quantified using the Agatston scoring method [20]. Coronary plaque characteristics 
were classified as follows [21,22]. Noncalcified coronary plaque was defined as any 
discernible structure that could be assigned to the coronary artery wall, had a CT 
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number below that of the contrast-enhanced coronary lumen but above that of the 
surrounding connective tissue, and could be identified in at least two independent planes. 
Any structure with a density of more than 130 HU that could be visualized separately 
from the contrast-enhanced coronary lumen, assigned to coronary artery wall, and 
identified in at least two independent planes was defined as calcified plaque. Partially 
calcified plaque was defined as having both calcified and noncalcified elements within a 
single plaque. One coronary plaque was assigned per coronary segment.  
 
Clinical outcomes 
   The follow-up information was gathered by either reviewing clinical visits or 
contacting general practitioners. Primary outcomes were examined included major 
adverse cardiovascular events (MACE) defined as any cause of death, acute coronary 
syndrome (ACS) and revascularization beyond 90 days after CTA. ACS was defined as 
a non-ST elevation and ST elevation myocardial infarction or unstable angina resulting 
in admission to the hospital. Patients undergoing coronary revascularization within 90 
days were censored at the time of the intervention. 
 
Statistical Analysis 
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   Continuous variables are expressed as means ± standard deviation (SD) or median 
and interquartile range for non-normally distributed data, and categorical variables as 
frequencies and percentages. The two groups divided by median BNP were compared 
using the chi-square test for nominal variables, student t test or Mann-Whitney U test 
for continuous variables. Univariable and multivariable logistic regression analysis was 
used to assess the association between BNP and the presence of obstructive CAD. 
Variables, including multivariable regression model, were those that achieved statistical 
significance (P<0.05) or were close to significance (P<0.10) in the univariable analysis. 
Survival analysis was performed by applying the Kaplan-Meier method and log-rank 
test. To compare the accuracy of BNP and the Duke clinical score, receiver operating 
characteristics (ROC) curves were generated and the area under the curve (AUC) was 
calculated. The net reclassification improvement was determined by assessing net 
improvement in risk classification [23]. Reclassification tables were constructed as a 
further measure to assess any incremental value for BNP in improving the risk 
classification afforded by the Duke clinical score using the risk categories <15%, 15% 
to ≤30%, 30% to ≤45%, and >45%. Statistical significance was accepted for 2-sided 
probability values of <0.05. Statistical analysis was performed with EZR (Saitama 
Medical Center, Jichi Medical University, Japan), which is a graphical user interface for 
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the R statistical analysis program (The R Foundation for Statistical Computing, version 
2.13.0) [24] and statistical package R version 3.1.1. 
 
Results 
Baseline characteristics 
   The mean patient age was 64±11 years, and 402 patients (42.4%) were women. The 
presence of any plaques was detected in 568 patients (60.0%). Among these 568 
patients with coronary plaques, calcified plaques were present in 463 (81.5%), 
noncalcified plaques in 283 (50.0%), and partially calcified plaques in 169 (29.8%) 
patients. Nonobstructive CAD was detected in 297 (31.4%) and normal arteries in 384 
(40.6%) patients. Obstructive CAD was found in 265 (28.0%) patients. Mean BNP level 
in patients with obstructive CAD was significant higher than those without obstructive 
CAD (26.2 ± 30.2 pg/ml vs 51.7 ± 106.6 pg/ml; P<0.001). The Duke clinical score was 
low (<30%) in 242 patients (25.5%), intermediate (30–70%) in 345 patients (36.3%), 
and high (>70%) in 360 patients (38.0%). The median Agatston score was 5 
(Interquartile range 0–118).  
The baseline characteristics of the 947 patients according to median BNP are shown 
in Table 1. Patients with BNP above median were older, more often female, and more 
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often had a lower eGFR and LDL level. The prevalence of hypertension was 
significantly higher in patients with BNP above median, but that of history of smoking, 
family history of CAD, diabetes mellitus, and dyslipidemia were similar regardless of 
BNP level. Prevalence of undergoing revascularization within 90 days after CTA were 
significantly higher in patients with BNP above median than those with BNP below 
median (P<0.001). 
CTA results and the Duke clinical score are shown in Table 2. The prevalence of 
obstructive CAD, one-vessel disease, two-vessel disease, and three-vessel or left main 
disease was significantly higher in patients with BNP above median than those with 
BNP below median. Numbers of total plaque, calcified plaque, noncalcified plaque, and 
partially calcified plaque were increased as BNP levels increased. The prevalence of 
high Duke clinical score was significantly higher in patients with BNP above median 
than those with BNP below median (P<0.001). 
The distribution of BNP within CAD is shown in Figure 2. As the severity of CAD 
increased, there was a significant increase in BNP level (P<0.001). The mean BNP was 
23.1 (SD 29.6) pg/ml in patients with normal arteries, 30.4 (SD 30.6) pg/ml in patients 
with nonobstructive CAD, and 51.7 (SD 106.5) pg/ml in patients with obstructive CAD. 
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Clinical outcomes 
   Median follow-up periods was 37 months (interquartile range 21 to 55 months). 
Coronary revascularization within 90 days after CTA was performed in 123 (13.0%) 
patients. Excluding patients undergoing coronary revascularization within 90 days after 
CTA, 42 (4.4%) patients experienced MACE, of which 11 patients died (1.2%), 9 
patients experienced ACS (1.0%) and 22 (2.6%) patients undergoing late coronary 
revascularization due to ischemic-related CAD. Kaplan-Meier curves showed BNP 
above median was significantly associated with MACE (P=0.001) (Figure 3). 
 
Multivariable logistic regression analysis for the prediction of obstructive CAD 
   Multivariable logistic regression analysis demonstrated that BNP above median  
(odds ratio [OR], 2.55; 95% confidence interval [CI], 1.79–3.63; P<0.001) was 
independent predictors of obstructive CAD as compared with BNP below median (Table 
3).  
 
Incremental value of BNP in addition to the Duke clinical score for the prediction of 
obstructive CAD 
   The AUCs for detecting obstructive CAD for BNP, Duke clinical score, and 
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composite of BNP and Duke clinical score were 0.673, 0.714, and 0.745, respectively 
(Figure 4). The AUC for the composite of BNP and Duke clinical score was 
significantly higher than the AUC for BNP alone and for Duke clinical score alone 
(P<0.001, for both). Reclassification of patients when predicting obstructive CAD based 
on BNP and Duke clinical score instead of Duke clinical score alone are summarized in 
Table 4. In patients with obstructive CAD, 42 patients (15.7%) correctly moved upward 
and 41 patients (15.4%) incorrectly moved downward in the classification. In patients 
without obstructive CAD, 39 patients (5.7%) incorrectly moved upward and 134 
patients (19.6%) correctly moved downward in the classification. Continuous net 
reclassification improvement was calculated at 0.39 (95% CI, 0.26–0.53; P<0.001). 
     
Discussion 
   In this study of patients with suspected CAD undergoing CTA, we scrutinized the 
diagnostic value of BNP. We report three major finding with the potential to improve the 
diagnosis of CAD: First, BNP levels were significantly higher in patients with 
obstructive CAD than in those without CAD. Second, the prediction of obstructive 
CAD with BNP was independent of conventional cardiovascular risk factors. Third, 
BNP added incremental improvement to conventional cardiovascular risk factors in 
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predicting obstructive CAD. Critical coronary stenosis is associated with worse 
cardiovascular outcomes depending on the location, functional significance, and extent 
of coronary atherosclerosis [25]. Patients with obstructive CAD on CTA have a worse 
long-term cardiovascular prognosis than those without obstructive CAD [26]. Therefore, 
the prediction of obstructive CAD on CTA is important in clinical practice. Although 
some previous studies have demonstrated that BNP is associated with CAD [11,12], a 
few reports have suggested that elevated BNP in patients with suspected CAD on CTA 
are associated with the presence of obstructive CAD. To our knowledge, this is the first 
study to elucidate the incremental value of BNP for the diagnosis of obstructive CAD 
on CTA. 
    BNP and NT-proBNP are widely used clinically as biomarkers for evaluating 
patients with heart failure [27]. However, few studies have investigated the association 
between obstructive CAD on CTA and BNP levels. In patients with stable CAD, 
myocardial ischemia, independent of LV dysfunction, might be a cause of elevated BNP 
[28,29]. NT-proBNP is increased in patients with CAD and correlates closely with 
disease severity [30,31]. These results might lead to the hypothesis that myocardial 
ischemia and CAD are major causes of the release of BNP. An increase in BNP as a 
response to myocardial ischemia can be explained by an increase in the LV filling 
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pressure, which occurs early in the ischemic cascade. However, because natriuretic 
peptides and their receptors are abundantly present in atherosclerotic plaques in human 
coronary arteries, atherosclerosis itself may be a cause of an elevated BNP level [32]. In 
the present study, the number of plaque was significantly higher in patients with a 
higher BNP level. This might explain the mechanism by which the higher BNP level is 
associated with coronary plaque burden. 
      The observed relation between BNP and obstructive CAD is in accordance with 
previous studies. Some studies have investigated the diagnostic performance of BNP 
and NT-proBNP in patients with suspected CAD. BNP in one study was not 
independently associated with CAD, but this study based the diagnosis of CAD on 
coronary catheterization findings [33]. Weber et al. [30] has demonstrated that 
NTproBNP was an independent predictor for obstructive CAD and closely linked to the 
number of diseased vessel as assessed by coronary angiography. In their study, AUC of 
NTproBNP for the predicting obstructive CAD was 0.72. Lee G et al. [34] has showed 
that combining BNP at rest and clinical judgment increased diagnostic accuracy 
regarding the presence of myocardial ischemia evaluated by rest/bicycle myocardial 
perfusion single-photon emission computed tomography. BNP at rest and clinical 
judgement achieved an AUC of 0.69 and 0.70 respectively. Clinical judgment added to 
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BNP improved the AUC to 0.75. Our data reveal that BNP is an independent predictor 
of the presence of obstructive CAD and added to cardiovascular risk factors have 
incremental value for the predicting obstructive CAD as assessed by CTA.  
   Cut off value of BNP for the predicting obstructive CAD in this study was quite low 
(25.4 pg/ml) when compared with contemporary thresholds used for the diagnosis of 
heart failure (100 pg/ml) [35], because we excluded patients with atrial fibrillation, left 
ventricular hypertrophy and previous myocardial infarction, which are known to be 
associated with cardiomyocyte damage and elevations in BNP regardless of the 
presence of coronary artery disease [36]. Our study suggests that BNP has the potential 
to become a serum biomarker that will improve identification of patients with 
obstructive CAD. We acknowledge that AUC of 0.745 for BNP plus Duke clinical score 
is suboptimal and there are remaining challenges to establish the role of non-invasive 
examination in the diagnosis of CAD. 
 
Study Limitations 
   Patients with LV dysfunction, atrial fibrillation, and previous heart failure were 
excluded. Therefore, the value of BNP in diagnosing obstructive CAD in these 
subgroups is unknown, and the results of our study cannot necessarily be generalized to 
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those patients. This may have introduced bias due to referral characteristics. Some 
previous studies have demonstrated that high sensitive troponins correlated with 
angiographic atherosclerotic extent and burden [37]. However, high sensitive troponins 
were not available in this study, we could not compare BNP value with high sensitive 
troponins. Finally, we analyzed the data from a single institution. Therefore, careful 
attention should be paid when the results are generalized and extrapolated. 
 
Conclusion 
BNP might provide incremental improvement in the detection of obstructive CAD on 
CTA when combined with a conventional cardiovascular risk score. 
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Figure legends 
 
Figure 1. Study population.  
BNP, B-type natriuretic peptide; CTA, computed tomography angiography; HCM, 
hypertrophic cardiomyopathy; LVEF, left ventricular ejection fraction; LVH, left 
ventricular hypertrophy. 
 
Figure 2. Distribution of plasma BNP levels according to the severity of CAD.  
BNP, B-type natriuretic peptide; CAD, coronary artery disease. 
 
Figure 3. Kaplan-Meier curves for MACE-free survival according to median of BNP. 
BNP, B-type natriuretic peptide, MACE, major adverse cardiac events.  
 
Figure 4. AUC for detecting obstructive CAD for BNP, Duke clinical score, and the 
composite of both.  
AUC, area under curve; BNP, B-type natriuretic peptide; CAD, coronary artery disease; 
DCS, Duke clinical score.  
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Appendix. 
Duke clinical score was calculated as 
            1/(1+e-x) 
where e = base of natural logarithm 
     x = ay1 + a2y2 + … + akyk + B 
where y1, y2, …, yk are the characteristics,  
     a1, a2, …, ak are the corresponding logistic regression coefficients, and  
     B is the intercept term (in this case, −7.376).  
The predictive characteristics are listed below with their coefficients: 
Characteristics   Coefficient 
Age 
 
0.1126 
Sex (0 = male, 1 = female) 
 
−0.328 
Age * Sex (interaction) 
 
−0.0328 
Typical angina (1 if present) 
 
2.581 
Atypical angina (1 if present) 
 
0.976 
History of MI (1 if present) 
 
1.093 
ECG Q waves (1 if present) 
 
1.213 
History of MI * Q waves (interaction) 0.741 
Smoking (1 if present) 
 
2.596 
Hyperlipidemia (1 if present) 
 
1.845 
Diabetes (1 if present) 
 
1.845 
ECG ST-T wave changes (1 if present) 0.637 
Age * Smoking (interaction) 
 
−0.0404 
Age * Hyperlipidemia (1 if present) −0.0251 
Sex * Smoking (interaction) 
 
0.55 
ECG, electrocardiogram; MI, myocardial infarction.  
 
Table 1. Baseline patients characteristics by median BNP levels  
 
BNP below median 
(<20.3 pg/ml) 
n=476 
BNP above median 
(≥20.3 pg/ml) 
n=469 
P Value 
Age, yrs 60.7 ± 10.8 67.7 ± 9.6 <0.001 
Female 180 (37.8) 211 (45.0) 0.029 
BMI, kg/m2 24.6 ± 4.5 23.7 ± 4.4 0.023 
Family history of CAD 149 (31.3) 147 (31.3) 1.000 
LVEF, % 64.0 ± 7.4 64.6 ± 8.1 0.223 
Smoker 217 (45.6) 195 (41.6) 0.238 
Diabetes mellitus 94 (19.7) 116 (24.7) 0.071 
Dyslipidemia 227 (47.7) 198 (42.2) 0.102 
Hypertension 257 (54.0) 287 (61.2) 0.025 
LDL, mg/dl 126.1 ± 32.9 119.0 ± 34.7 0.001 
HDL, mg/dl 56.5 ± 16.0 59.2 ± 30.6 0.089 
TG, mg/dl 163.4 ± 107.6 153.0 ± 148.8 0.221 
CRP, mg/dl 0.21 ± 0.66 0.31 ± 1.18 0.106 
eGFR, ml/min/1.73 m2 63.4 ± 16.6 59.8 ± 16.9 0.001 
Exertional chest pain 113 (23.7) 136 (29.0) 0.076 
Atypical chest pain 213 (44.7) 183 (39.0) 0.075 
Dyspnea 36 (7.6) 42 (9.0) 0.444 
Revascularization  
within 90 days 42 (8.8) 79 (16.8) <0.001 
Data are expressed as mean value ± SD or number of patients (percentage).  
BMI, body mass index; BNP, B-type natriuretic peptide; CAD, coronary artery 
disease; CRP, C reactive protein; eGFR, estimated glomerular filtration rate; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein; LVEF, left ventricular 
ejection fraction; TG, triglyceride. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Computed tomography angiography results and Duke clinical score 
  BNP below median (<20.3 pg/ml) 
n = 476 
BNP above median 
(≥20.3 pg/ml) 
n = 469 
P Value 
Obstructive CAD 82 (17.2) 182 (38.8) <0.001 
One-vessel 56 (11.8) 105 (22.4) <0.001 
Two-vessel 15 (3.2) 48 (10.2)  
Three-vessel or left main 11 (2.3) 29 (6.2)  
Non-obstructive CAD 142 (29.8) 155 (33.0) 0.294 
Normal coronary arteries 252 (52.9) 132 (28.1) <0.001 
Total plaque 1.54 ± 2.25 2.98 ± 2.97 <0.001 
Calcified plaque 1.07 ± 1.79 1.97 ± 2.37 <0.001 
Non-calcified plaque 0.30 ± 0.72 0.63 ± 1.03 <0.001 
Partially calcified plaque 0.16 ± 0.51 0.37 ± 0.79 <0.001 
Calcium score* 0 [0, 52] 32 [0, 241] <0.001 
Duke clinical score, % 50.3 ± 28.2 60.7 ± 28.2 <0.001 
Data are expressed as mean value ± SD or number of patients (percentage). *Median and 
interquartile range.  
BNP, B-type natriuretic peptide; CAD, coronary artery disease. 
 
Table 3. Univariable and multivariable logistic regression analysis for the presence of 
obstructive CAD 
 Univariable Multivariable 
  OR 95% CI P value OR 95% CI P value 
BNP below median (<20.3 pg/ml) reference reference 
BNP above median (≥20.3 pg/ml) 3.05 2.25–4.12 <0.001 2.55  1.79–3.63 <0.001 
Age, per yrs 1.05  1.03–1.06 <0.001 1.04  1.02–1.06 <0.001 
CRP, per kg/m2 1.15  0.99–1.33 0.058 1.10  0.93–1.30 0.244 
Dyslipidemia 1.38  1.04–1.83 0.023 1.61  1.15–2.27 0.005 
Hypertension 2.07  1.54–2.79 <0.001 1.62  1.14–2.31 0.007 
Diabetes mellitus 2.14  1.56–2.94 <0.001 1.78  1.22–2.60 0.002 
eGFR, per ml/min/1.73 m2 0.96  0.95–0.97 <0.001 0.99  0.97–1.00 0.206 
Female 0.36  0.26–0.49 <0.001 0.31  0.20–0.48 <0.001 
Exertional chest pain  1.91  1.41–2.59 <0.001 1.93  1.29–2.89 0.001 
Atypical chest pain 0.56  0.41–0.75 0.001 0.85  0.57–1.26 0.422 
Dyspnea  1.27  0.80–2.00 0.311    
Family history 1.11  0.82–1.50 0.502    
BMI, per kg/m2 1.00  0.97–1.03 0.897    
LVEF, per % 0.99  0.97–1.01 0.491    
Smoker 1.11  0.83–1.47 0.483       
CI, confidence interval. OR, odds ratio. See Table 1 for other abbreviations.   
 
 
 
 
 
 
 
 
 
 
 
Table 4. Reclassification of study participants with or without obstructive CAD by BNP to 
a model containing the Duke clinical score 
Patients with obstructive CAD (n=266) 
 Model with Duke clinical score plus BNP 
Model with Duke 
clinical score <15% risk 
15% to <30% 
risk 
30% to 45% 
risk >45% risk Total 
<15% risk 24 4 2 1 31 
15% to <30% risk 1 36 7 1 45 
30% to 45% risk 0 22 54 27 103 
>45% risk 0 0 18 69 87 
Total 25 62 81 98 266 
Patients without obstructive CAD (n=681) 
Model with Duke clinical score plus BNP 
Model with Duke 
clinical score <15% risk 
15% to <30% 
risk 
30% to 45% 
risk >45% risk Total 
<15% risk 224 11 2 1 238 
15% to <30% risk 43 140 10 2 195 
30% to 45% risk 0 44 97 13 154 
>45% risk 0 0 47 47 94 
Total 267 195 156 63 681 
   
Continuous net reclassification improvement was calculated at 0.39 (95% CI, 0.26–0.53; 
P<0.001). 
BNP, B-type natriuretic peptide; CAD, coronary artery disease; CI, confidence interval. 
 
322 patients were excluded
39   with poor CTA imaging
78   with atrial fibrillation
26   with previous heart failure 
77   with lower LVEF (less than 50%)
29   with HCM or LVH
13   with  acute myocardial infarction
60   with missing BNP value
This study consisted of 947 patients. 
1269 patients with suspected coronary artery disease 
underwent CTA between April 2008 and June 2014. 
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